Clinical Trial Search

Primary: The Fronto-central Theta Absolute Power Change Rate — 0.14; -0.12 ratio

Primary: Change in Montreal Cognitive Assessment (MoCA) Score — 0.56; 1.38; -0.75; 0.50 score on a scale

Primary: Mean Score of Montreal Cognitive Assessment (MoCA) at Visit 5 in Comparison With Reference Score at Visit 0 — 25.72; 23.95; 4.22; 2.17 score on a scale

Primary: Number of Participants With Reperfusion Injury Hemorrhagic Transformation — 3 participants

Primary: Percent Change in Cerebral Blood Flow (CBF) — 0; 25 percentage increase in CBF

Primary: Blood Pressure and Heart Rates;

Primary: Stroke or Death in the Territory of Qualifying Artery — 5 Participants — p=0.08

Primary: Mean MoCA Score at Week 1 and the End of the 12-week Therapy — 19.42; 24 score on a scale — p=<0.00001

Primary: Number of Participants With Progression of Symptomatic Intracranial Stenosis — 20; 32 participants

Primary: Percentage of Regions With Collateral Versus Antegrade Blood Flow (Sensitivity) Correctly Identified Using MRI With Xenon Contrast Agent (Specificity) — 81.7; 88.9…

Primary: Number of Patients With Cerebrovascular Events, Cardiovascular Events or Death. — 0; 2; 2; 1 participants

Primary: Mean Arterial Pressure-Middle Cerebral Artery Blood Velocity Very Low Frequency Phase (Radians) — 1.38; 1.12; 1.40; 1.60 Radians — p=0.05

Primary: Sleep Apnea Diagnosis Rate — 58; 5 participants

Primary: Feasibility of Phase III Trial — 20; 21; 10; 4 Participants

Primary: The Changes of Middle Cerebral Artery (MCA) and Basilar Artery (BA) Pulsatility Index (PI) at 14 and 90 Days From the Baseline Transcranial Doppler (TCD) Study — 0.07…

Primary: Change in Corticomotor Excitability — 0.38; 0.37; 0.41; 0.37 millivolt (mV)

Primary: Numbers of Patients With First Occurence of Stroke — 82; 119 participants — p=0.0357

Primary: Incidence of Death From Any Cause or Myocardial Infarction — 123; 129 Participants

Primary: Any Stroke or Death Within 30 Days of Enrollment or Any Revascularization Procedure OR an Ischemic Stroke in the Territory of the Symptomatic Intracranial Artery Beyond…

Primary: Changes in Brain Activation — 48.5; -30 voxels

Primary: Evidence of Carotid Artery or Intracranial Artery Atherosclerosis Confirmed by Vascular Ultrasonography — 96; 1063; 826; 241 artery numbers

Primary: Change in Action Research Arm Test (ARAT) Score — 6.2 units on a scale — p=0.002

Primary: Composite Cognitive Score — 45.5; 47.9 units on a scale

Primary: Maximum Tolerated Dose (MTD) of DDFPe Evaluated by Number of Dose Limiting Toxicities — 0; 0; 0; 0 Dose Limiting Toxicities

Primary: Proportion of Subjects Whose Fugl-Meyer Motor Total Score (FMMS) Improved by ≥ 10 Points at Month 6 From Baseline — 7; 9; 7; 46 Participants — p=0.6743

Primary: Primary Outcome — 27; 21 Participants

Primary: Number of Subjects With Treatment Emergent Adverse Events (TEAEs) — 1; 1; 0; 3 Participants

Primary: Dynamic Cerebral Autoregulation Parameter: Phase Difference(PD) in Degree — 45.87 degree

Primary: Composite Neurological Outcome of Clinical Stroke or New Ischemic Brain Lesion on Diffusion Weighted MRI or Neurocognitive Dysfunction 4 to 6 Weeks After Surgery. — 79…

Primary: Primary Composite Outcome: Death From Cardiovascular Causes, Myocardial Infarction, or Hospitalization for Unstable Angina, Heart Failure, or Resuscitated Cardiac Arrest…